 |
市场调查报告书
商品编码
1378698
间质性膀胱炎治疗药物市场：依药物类别、按类型、按给药途径、按配销通路、按地区Interstitial Cystitis Drugs Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
预计2023年全球间质性膀胱炎治疗药物市场将达2.349亿美元，预测期内（2023-2030年）年复合成长率为6.9%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 2.349 亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期年复合成长率 | 6.90% | 2030年市场规模预测 | 3.756 亿美元 |
图 1. 2023 年间质性膀胱炎药物的全球市场占有率(%)（依药物类别）
间质性膀胱炎（IC），也称为膀胱疼痛症候群，是一种导致膀胱和骨盆周围区域反覆不适和疼痛的疾病。即使是同一个人，症状也因情况而异。您的膀胱和骨盆区域可能会感到轻微的不适、压力、压痛或剧烈疼痛。症状包括迫切需要排尿、频繁需要排尿或这些症状的组合。当膀胱充满尿液或排空时，疼痛的强度可能会改变。对于女性来说，月经期间症状往往会恶化。您在阴道性交时也可能会感到疼痛。
在间质性膀胱炎或膀胱疼痛症候群中，膀胱壁会发炎，并且可能会出现疤痕或变硬。汉纳溃疡是膀胱壁上的皮肤破损斑块，10% 的 IC 患者会出现这种情况。一些患有 IC 或 PBS 的人可能会发现他们的膀胱容纳的尿液较少，并且排尿更频繁。
市场动态
间质性膀胱炎患者治疗的活性化预计将在预测期内推动市场成长。例如，2023年4月10日，瑞士洛桑大学医院Center Hospitalier Universitaire Vaudois与瑞士伯尔尼大学医院的研究人员合作，研究间质性膀胱炎和膀胱疼痛症候群，并宣布开始临床研究评估术前口服免疫营养（IN）对病人术后併发症影响的试验研究。该研究目前处于第三阶段，正积极招募患者。
本次测试的主要特点
- 本报告对全球间质性膀胱炎治疗药物市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030）的市场规模和復合年度（年复合成长率）。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
- 根据公司亮点、产品系列、主要亮点、业绩和策略等参数对全球间质性膀胱炎治疗药物市场的主要企业进行了分析。
- 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
- 全球间质性膀胱炎治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
- 透过用于分析全球间质性膀胱炎治疗药物市场的各种策略矩阵，将促进相关人员的决策。
目录
第1章研究目的与前提
- 研究目标
- 先决条件
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第3章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 市场机会
- 影响分析
- 最近的药物上市以及历史蓝图
- 流行病学
- 管道分析
- 收购与合作
- 法规场景
- 主要进展
- PEST分析
第4章全球间质性膀胱炎治疗药物市场－COVID-19的影响分析
- 经济影响
- COVID-19 的流行病学
- 对需求和供给的影响
第5章全球间质性膀胱炎治疗药物市场，依药物类别，2018-2030
- 非类固醇消炎剂
- 三环抗忧郁药物
- 戊聚醣多硫酸钠（Elmiron）
- 二甲亚砜 (DMSO)
- 其他（抗组织胺等）
第6章全球间质性膀胱炎治疗药物市场，依类型，2018-2030
- 非溃疡性
- 溃疡性的
第7章全球间质性膀胱炎治疗药物市场，依给药途径，2018-2030
- 口服
- 膀胱内
第8章全球间质性膀胱炎治疗药物市场，依配销通路，2018-2030
- 医院药房
- 零售药房
- 网路药房
第9章全球间质性膀胱炎治疗药物市场，按地区，2018-2030
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第10章竞争形势
- 公司简介
- AbbVie Inc.
- Hyloris Pharmaceuticals SA
- TAGCyx Biotechnologies
- KYORIN Pharmaceutical Co., Ltd.
- PureTech Health
- Vaneltix
- Red Leaf Medical Inc.
- Bayer AG
- Eli Lilly and Co.
- Johnson &Johnson（Janssen Pharmaceuticals）
- Mylan NV（Viatris Inc.）
- Perrigo Co. Plc
- Pfizer Inc.
- Seikagaku Corp.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- ImprimisRx（Harrow Health, Inc.）
第11章章节
- 参考
- 调查方法
简介目录
Product Code: CMI4488
The global interstitial cystitis drugs market is estimated to be valued at US$ 234.9 million in 2023 and is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 234.9 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 6.90% | 2030 Value Projection: | US$ 375.6 Mn |
Figure 1. Global Interstitial Cystitis Drugs Market Share (%), By Drug Class, 2023
Interstitial cystitis (IC), also known as painful bladder syndrome, is a condition that results in recurring discomfort or pain in the bladder and the surrounding pelvic area. The symptoms can differ between cases and even within the same person.People may experience mild discomfort, pressure, tenderness, or intense pain in the bladder and pelvic area. Symptoms may include an urgent need to urinate, a frequent need to urinate, or a combination of these symptoms. Pain may change in intensity as the bladder fills with urine or as it empties. Women's symptoms often get worse during menstruation. They may sometimes experience pain during vaginal intercourse.
In interstitial cystitis or painful bladder syndrome, the bladder wall may be irritated and become scarred or stiff. Hunner's ulcers, patches of broken skin found on the bladder wall, are present in 10 percent of people with IC. While some people with IC or PBS find that their bladder cannot hold much urine, which increases the frequency of urination.
Market Dynamics
Rising research and development activities for the treatment of patients suffering from interstitial cystitis are expected to propel market growth over the forecast period. For instance, on April 10, 2023, Centre Hospitalier Universitaire Vaudois, a university hospital in Lausanne, Switzerland, in collaboration with researchers of the University Hospital based in Bern, Switzerland, announced the initiation of a clinical trial study to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing interstitial cystitis and painful bladder syndrome, which is currently in phase 3 and actively recruiting patients.
Key features of the study:
- This report provides an in-depth analysis of the global interstitial cystitis drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global interstitial cystitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie Inc., Hyloris Pharmaceuticals SA, TAGCyx Biotechnologies, KYORIN Pharmaceutical Co., Ltd., PureTech Health, Vaneltix, Red Leaf Medical Inc., Bayer AG, Eli Lilly and Co, Johnson & Johnson (Janssen Pharmaceuticals), Mylan NV (Viatris Inc.), Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and ImprimisRx (Harrow Health, Inc.)
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global interstitial cystitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interstitial cystitis drugs market
Interstitial Cystitis Drugs Market Detailed Segmentation:
- By Drug Class:
- Non-steroidal Anti-inflammatory Drugs
- Tricyclic Antidepressants
- Pentosan Polysulfate Sodium (Elmiron)
- Dimethyl Sulfoxide (DMSO)
- Others (Anti-histamines, etc.)
- By Type:
- Non-ulcerative
- Ulcerative
- By Route of Administration:
- Oral
- Intravesical
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
- Company Profiles
- AbbVie Inc.
- Hyloris Pharmaceuticals SA
- TAGCyx Biotechnologies
- KYORIN Pharmaceutical Co., Ltd.
- PureTech Health
- Vaneltix
- Red Leaf Medical Inc.
- Bayer AG
- Eli Lilly and Co.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Mylan NV (Viatris Inc.)
- Perrigo Co. Plc
- Pfizer Inc.
- Seikagaku Corp.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- ImprimisRx (Harrow Health, Inc.)
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launch with Historic Roadmap
- Epidemiology
- Pipeline Analysis
- Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Interstitial Cystitis Drugs Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Interstitial Cystitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Non-steroidal Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Tricyclic Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Pentosan Polysulfate Sodium (Elmiron)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Dimethyl Sulfoxide (DMSO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others (Anti-histamines, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
6. Global Interstitial Cystitis Drugs Market, By Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Non-ulcerative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Ulcerative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
7. Global Interstitial Cystitis Drugs Market, By Route of Administration, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Intravesical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
8. Global Interstitial Cystitis Drugs Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
9. Global Interstitial Cystitis Drugs Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- AbbVie Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hyloris Pharmaceuticals SA
- TAGCyx Biotechnologies
- KYORIN Pharmaceutical Co., Ltd.
- PureTech Health
- Vaneltix
- Red Leaf Medical Inc.
- Bayer AG
- Eli Lilly and Co.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Mylan NV (Viatris Inc.)
- Perrigo Co. Plc
- Pfizer Inc.
- Seikagaku Corp.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- ImprimisRx (Harrow Health, Inc.)
11. Section
- References
- Research Methodology
- About us and Sales Contact
